Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source outlines the potential effects of treatments commonly used in trichology on SARS-CoV-2 infection and offers a guide for managing trichological patients during the COVID-19 era, addressing the challenges of safely visiting and treating patients.

This review discusses the use of stem cell therapies for hair diseases, highlighting promising results but reporting no new clinical findings.

In this study, the authors found that a botanical extract with anti-inflammatory and anti-oxidative properties stabilized hair loss and preserved natural hair pigmentation and strength over six months.

This study observed that dermatologists predominantly prescribed topical treatments for skin disorders in pregnant women, with pruritus and urticaria being the most common conditions.

In this pilot study, eyebrow mesotherapy was reported to achieve clinically apparent thickening and darkening of eyebrows, with 8 out of 12 patients satisfied with the results after 15 days.

Treatments for acute leukaemia lead to high remission rates, but relapses occur, requiring ongoing advancements in care.

This study found that a single injection of platelet-rich stroma significantly increased hair density in men with androgenetic alopecia within 6 to 12 weeks, with no reported side effects.

This study found that transplanting trichogenous dermal cells significantly enhanced the restoration of in vivo-damaged hair follicles in a nude rat model, with a combination of dermal papilla and sheath cells proving more effective than either cell type alone.

This review discusses the use of platelet-rich plasma as a treatment for androgenetic alopecia and highlights the need for standardized protocols, reporting no new clinical results.

This review discusses the various off-label treatments for alopecia areata, highlighting that these therapies may promote hair growth but are not curative.

This pilot clinical trial observed that combining subcision using a blunt cannula with platelet-rich plasma injections and microneedling for post-acne rolling scars was associated with a significant positive correlation between physician satisfaction and age of acne onset.

This review discusses novel treatments for androgenetic alopecia, including therapies like platelet-rich plasma and adipose-derived stem cells, and reports no new clinical results.

This retrospective study found that treatment with autologous plasma rich in growth factors increased hair density and improved hair follicle health in patients with androgenetic alopecia, with no reported adverse effects.

This review discusses current and emerging drug therapies for treating androgenetic alopecia and alopecia areata, and reports no clinical results; it highlights a need for improved and novel treatments.

This review summarizes current and emerging treatments for common hair loss conditions, highlighting good evidence for androgenetic alopecia but noting the lack of long-term data for alopecia areata and cicatricial alopecias.

This article discusses less commonly used and experimental treatments for vitiligo, focusing on therapies other than psoralen, but does not report new clinical results.

Photodynamic therapy was effective in treating multiple scalp basal cell carcinomas with minimal side effects and good cosmetic results.

This paper reviews treatments for lichen planopilaris, including low-level laser therapy, but reports no new clinical results and highlights the need for further research.

In this study, manually prepared platelet-rich plasma did not show significant improvement in hair count or anagen hair proportion for men with androgenetic alopecia.

This review discusses various treatments for noncicatricial alopecias, such as androgenetic alopecia and alopecia areata, including mesotherapy, microneedling, and platelet-rich plasma therapy, noting that outcomes vary across these procedures.

This review provides a clinical guide for safely using dermo-aesthetic treatments to improve the quality of life for oncology patients dealing with treatment-related side effects, emphasizing the importance of consulting with an oncologist before undergoing such procedures.

This study reviewed existing literature on mesotherapy as a treatment for androgenetic alopecia, finding that it may improve hair density and thickness with generally mild side effects, but emphasized variability in study designs limits the strength of these conclusions.

This study reviews existing literature on regenerative therapy for androgenetic alopecia, highlighting that integrating growth factors, biotin, D-pantenol, and other active ingredients using the Vittahair protocol may enhance hair follicle regeneration, increase hair density, and improve hair quality, providing a precise and evidence-based treatment alternative.

Treatments for hair loss vary, but cell-based options may be the future.

This study found that overexpression of Wnt1a in bone marrow mesenchymal stem cells enhanced mouse hair follicle regeneration and promoted hair cycling.

This study found that N-acetylcysteine effectively prevented cyclophosphamide-induced alopecia in rats, and ImuVert plus N-acetylcysteine prevented alopecia from a cyclophosphamide-cytarabine combination.

This study's meta-analysis reported that PRP injections significantly increased hair density compared to baseline and placebo in androgenetic alopecia patients, supporting its use as a beneficial treatment.

This review discusses the potential autoimmune pathogenesis and various contributing factors of alopecia areata, noting that current treatments remain palliative while emerging therapies offer new hope for extensive cases.

This paper reviews the use of interferons, particularly alfa interferon, in treating cutaneous T-cell lymphoma, noting its substantial efficacy both alone and in combination therapies with predictable, generally well-tolerated side effects.

This study found that while some patients with severe alopecia areata responded to high-dose prednisolone, the response was inconsistent and the therapy's risks prevent recommending it for general use.